Development of the 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria, Phase III ‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions
Arthritis Care & Research · 2026
DOI: 10.1002/acr.25599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Medha Barbhaiya und 30 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Special Surgery, Weill Cornell Medicine, New York, NY. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Rheumatology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Rheumatology Research Foundation, NIAMS NIH HHS, King's BHF Centre for Award Excellence.
Abstract (Originalsprache)
Objective
The 2023 American College of Rheumatology (ACR)/EULAR antiphospholipid syndrome (APS) classification criteria aim to identify patients with a high likelihood of APS for research. Phases I/II of our four‐phase methodologic approach resulted in 27 candidate criteria organized in clinical and laboratory domains. Here, we summarize phase III efforts to reduce and refine criteria using patient scenarios.
Methods
Using standardized definitions for candidate criteria, the Steering Committee collected antiphospholipid antibody (aPL)–positive cases referred for “suspected APS.” Treating physicians assessed APS case likelihood using a Likert scale. Poisson regression calculated risk ratios (RRs) and 95% confidence intervals (CIs) to quantify the direction and size of the association of candidate criteria with “highly likely” versus “equivocal or unlikely” APS, which guided Steering Committee candidate criteria refinement and organization.
Results
We collected 314 suspected APS cases (137 [44%] highly likely and 177 [56%] equivocal/unlikely APS). Provoking venous thromboembolism (VTE) or arterial thrombosis (AT) risk factors reduced the size of the association with highly likely APS (RR 4.31 [95% CI 2.11–8.78] to RR 1.56 [95% CI 0.89–2.75] for VTE and RR 3.48 [95% CI 1.91–6.32] to RR 1.64 [95% CI 0.77–3.51] for AT). Persistent lupus anticoagulant, anticardiolipin IgG antibody ≥40 U, and anti–β 2 ‐glycoprotein‐I IgG antibody ≥40 U were positively associated with highly likely APS (all P < 0.05). Eventually, items within eight additive and independent clinical and laboratory domains were refined.
Conclusion
Referred suspected APS cases provided insight into associations of individual candidate criteria with APS likelihood. RR analyses helped refine items and organize the draft classification system into eight additive and independent clinical and laboratory domains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital for Special Surgery, Weill Cornell Medicine, New York, NY.
- CHRU de Nancy, University Hospital of Nancy, INSERM UMR-S 1116, University of Lorraine, Nancy, France.
- Hospital for Special Surgery, New York, NY.
- ABC Medical Center, Mexico City, Mexico.
- University of São Paulo, São Paulo, Brazil.
- Children's Hospital, University Medical Center, University of Ljubljana, Ljubljana, Slovenia.
ORCID-Profile: Medha Barbhaiya, Deanna Jannat-Khah, Guilherme Ramires de Jesús, Jose A Gomez Puerta, Michelle Petri, Savino Sciascia, Maria Tektonidou, Karen H Costenbader, Doruk Erkan
Förderung
- Rheumatology Research Foundation
- NIAMS NIH HHS
- King's BHF Centre for Award Excellence
- American College of Rheumatology
- European Alliance of Associations for Rheumatology
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Barbhaiya, M., Zuily, S., Jannat-Khah, D., Amigo, M. C., Andrade, D., Avcin, T., Bertolaccini, M. L., Branch, D. W., Costedoat-Chalumeau, N., de Jesús, G. R., Devreese, K. M. J., Garcia, D., Gomez Puerta, J. A., Guillemin, F., Levine, S. R., Levy, R. A., Lockshin, M. D., Ortel, T. L., Petri, M., …, & New APS Classification Criteria Collaborators (2026). Development of the 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria, Phase III ‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions. Arthritis Care & Research. https://doi.org/10.1002/acr.25599
Vancouver
Barbhaiya M, Zuily S, Jannat-Khah D, Amigo MC, Andrade D, Avcin T, et al. Development of the 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria, Phase III ‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions. Arthritis Care & Research. 2026. doi:10.1002/acr.25599
BibTeX
@article{Barbhaiya2026,
author = {Barbhaiya, Medha and Zuily, Stephane and Jannat-Khah, Deanna and Amigo, Mary-Carmen and Andrade, Danieli and Avcin, Tadej and Bertolaccini, Maria L and Branch, D Ware and Costedoat-Chalumeau, Nathalie and de Jesús, Guilherme Ramires and Devreese, Katrien M J and Garcia, David and Gomez Puerta, Jose A and Guillemin, Francis and Levine, Steven R and Levy, Roger A and Lockshin, Michael D and Ortel, Thomas L and Petri, Michelle and Sanna, Giovanni and Sciascia, Savino and Seshan, Surya V and Tektonidou, Maria and Wahl, Denis and Willis, Rohan and Yelnik, Cecile and Hendry, Alison and Naden, Ray and Costenbader, Karen H and Erkan, Doruk and New APS Classification Criteria Collaborators, New APS Classification Criteria Collaborators},
title = {Development of the 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria, Phase III ‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.25599}
}
EUVIMED